News search

REBOOT trial, coordinated by the CNIC, shows that treatment with beta-blockers provides no benefit to patients who experience an uncomplicated heart attack that leaves the contractile function of the heart intact.

A new study led by the CNIC has identified imidazole propionate (ImP), a metabolite produced by gut bacteria, as a driver of atherosclerosis— as a driver of atherosclerosis, the disease behind most heart attacks and strokes

A team from the CNIC has discovered the key role of conventional type 1 dendritic cells (cDC1) in atherosclerosis and has developed an experimental therapy with immunosuppressive nanoparticles that slows the progression of the disease in animal models.

A study led by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), in collaboration with the Instituto de Investigación Biomédica de Barcelona (IRB Barcelona), has identified the most effective subtype of dendritic cell for generating immune memory in response to cancer

The system provides specialised answers to biomedical questions, ensuring data privacy by operating exclusively within the CNIC

The study, published in JACC: CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves mitochondrial function, improves myocardial energetics, and prevents degenerative changes in heart structure

iFlpMosaics is a new technology presented in Nature Methods that allows the modification and study of gene function in mouse models, advancing research on diseases caused by somatic mutations, such as cancer and vascular malformations.

The new project, ‘The Placenta in Maternal and Fetal Cardiovascular Health and Disease’, aims to understand how the placenta influences cardiovascular health in mothers and their children, promising improvements in the prevention and treatment of related diseases